Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Patients with early-stage chronic kidney disease (CKD) are susceptible to changes in metabolic processes. Partial loss of kidney function leads to homoeostatic disturbances in bone and fatty tissue. The aim of this study was to investigate the association between plasma concentrations of Klotho protein, FGF23, leptin, adiponectin, osteocalcin, and bone mineral density (BMD) in patients with CKD in the pre-dialysis period. The study involved 52 patients with CKD and 23 patients with no kidney disease. In both groups, BMD, body mass index and serum or plasma concentrations of lipids, glucose, creatinine, calcium, phosphorus, parathormone, leptin, adiponectin, osteocalcin, Klotho, and FGF23 were measured. The group with CKD had statistically significant higher concentrations of leptin (p<0.001), parathormone (p<0.001), and osteocalcin (p<0.001) in comparison with the control group. Patients with CKD also had statistically significant lower BMD in the femoral neck in comparison with the control group. Osteocalcin correlated negatively with BMD. The results of our study suggest that elevated osteocalcin is the most sensitive marker of decreased bone mass in patients with CKD. Osteocalcin correlated negatively with BMD and GFR. The loss of bone mass in CKD patients was greatest in the femoral neck.

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0752-4615DOI Listing

Publication Analysis

Top Keywords

leptin adiponectin
12
kidney disease
12
association plasma
8
klotho protein
8
bone mineral
8
mineral density
8
chronic kidney
8
plasma concentrations
8
adiponectin osteocalcin
8
patients ckd
8

Similar Publications

Adipokines, including C1q/tumor necrosis factor (TNF)-related proteins (CTRPs), adiponectin, TNF-α, and leptin, are crucial bioactive molecules that are secreted by adipose tissue and circulate in the bloodstream. To date, 15 members of the CTRP family, which are collectively classified as part of the C1q/TNF superfamily, have been identified. Among these, CTRP3 stands out as a unique adipokine because of its distinct structural and functional properties.

View Article and Find Full Text PDF

Introduction: This study aimed to investigate the anti-obesity, hepatic protective, and metabolic effects of Sidr and Talh honey, two Saudi honey, in rats fed a high-fat diet (HFD) and examined some possible mechanisms of their action.

Methods: Adult rats were divided into eight groups ( = 8 each) and were administered HFD for 12 weeks, with or without oral doses of Sidr or Talh honey at 500, 700, and 1,000 mg/kg.

Results And Discussion: Talh honey significantly reduced body weight, fat mass, and adiposity markers, including mesenteric, subcutaneous, and epididymal fat, compared to the HFD group.

View Article and Find Full Text PDF

Background: Obesity and chronic inflammation are associated with cancer risk. We investigated the association between adipokines, inflammation markers, and cancer risk among Chinese men.

Methods: Using pre-diagnosis fasting plasma samples from 4,051 (6.

View Article and Find Full Text PDF

Background: Nicotinamide adenine dinucleotide phosphate (NADP)-dependent isocitrate dehydrogenases, isocitrate dehydrogenase enzyme (IDH)1 and IDH2, are crucial to normal glucose and lipid metabolism and to oxidative species handling. This study aimed to assess the probability of utilizing NADP-dependent isocitrate dehydrogenases deficiency as a biomarker of the progression of metabolically healthy obesity (MHO) to metabolic syndrome (MetS).

Methods: The study enrolled 120 participants.

View Article and Find Full Text PDF

Objective: This study aimed to systematically evaluate the effects of exercise interventions on metabolic and inflammatory biomarkers in cancer patients, and to identify potential dose-response relationships and modulatory mechanisms using Robust Variance Estimation (RVE) and MetaForest models.

Methods: A systematic search of five databases was conducted from inception to March 6, 2025, based on the PICOS framework. Randomized controlled trials involving exercise interventions of ≥4 weeks in adults (≥18 years) with cancer were included.

View Article and Find Full Text PDF